InsiderClue
Stocks · Health care · Services-Medical Laboratories

Caris Life Sciences, Inc.

CAI Clue Score63
United States Fiscal year ends December CIK 0002019410
$29.70 +8.00% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $29.70 −4.99% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 18 Jun 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2023Revenue306.1Operating income−319.6Net income−341.4EPS, diluted−13.24Fiscal year 2024Revenue412.3 +34.7%Operating income−257.1Net income−281.9EPS, diluted−10.66Fiscal year 2025Revenue812.0 +97.0%Operating income45.1Net income−68.1EPS, diluted−3.22
FY2023FY2024FY2025
Revenue 306.1 412.3 812.0
Growth +34.7% +97.0%
Operating income −319.6 −257.1 45.1
Net income −341.4 −281.9 −68.1
Growth
EPS, diluted −13.24 −10.66 −3.22

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2023Operating margin−104.4%Net margin−111.5%Free cash flow margin−97.5%Fiscal year 2024Operating margin−62.4%Net margin−68.4%Free cash flow margin−61.5%Fiscal year 2025Operating margin5.6%Net margin−8.4%Free cash flow margin8.2%
FY2023FY2024FY2025
Operating margin −104.4% −62.4% 5.6%
Net margin −111.5% −68.4% −8.4%
Free cash flow margin −97.5% −61.5% 8.2%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−276.1Capital expenditure−22.3Free cash flow−298.4Buybacks0.0Fiscal year 2024Operating cash flow−245.2Capital expenditure−8.4Free cash flow−253.6Buybacks0.0Fiscal year 2025Operating cash flow83.2Capital expenditure−16.3Free cash flow66.9Buybacks−0.1
FY2023FY2024FY2025
Operating cash flow −276.1 −245.2 83.2
Capital expenditure −22.3 −8.4 −16.3
Free cash flow −298.4 −253.6 66.9
Growth
Buybacks 0.0 0.0 −0.1

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2023Shareholders’ equity−2,145.0Fiscal year 2024Cash64.0Total debt379.5Net cash (debt)−315.6Shareholders’ equity−2,498.8Fiscal year 2025Cash796.3Total debt379.0Net cash (debt)417.3Shareholders’ equity577.3Debt to equity0.66
FY2023FY2024FY2025
Cash n/a 64.0 796.3
Total debt n/a 379.5 379.0
Net cash (debt) n/a −315.6 417.3
Shareholders’ equity −2,145.0 −2,498.8 577.3
Debt to equity n/a n/a 0.66

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
−104.4% −62.4% 5.6%
−111.5% −68.4% −8.4%
−111.5% −68.4% −8.4%
−97.5% −61.5% 8.2%
Spending
38.2% 27.6% 12.5%
48.7% 41.1% 27.7%
7.3% 2.0% 2.0%
Returns
n/a n/a −11.8%
n/a −82.0% −6.0%
Balance and payout
n/a n/a 0.66
n/a 180.6% 48.7%
n/a n/a 0.2%